Abstract
Antibacterial resistance, particularly that resulted from by extended-spectrum betalactamases (ESBLs), is increasing at an alarming pace as a direct consequence of extensive antibiotic usage, leading to an increase in the number of infections that are difficult to be eradicated.. Klebsiella pneumoniae and Staphylococcus epidermidis were the most common pathogens grown from 156 (18.5%) samples. Escherichia coli AmpC-producing ESBL due to worldwide Escherichia coli proliferation, researchers tested 10,780 clinical strains for decreased susceptibility. Nevertheless, genes and multilocus sequences varied widely among nations. CTX-M enzymes caused ESBL to rise 53% from 2012 to 2017. Levofloxacin, cefepime, piperacillintazobactam, and meropenem may detect ESBL-E bacteremia risk. During the COVID-19 pandemic, Acinetobacter baumannii had the most resistant strains, followed by Klebsiella pneumonia, Escherichia coli, and Pseudomonas aeruginosa. To combat the epidemic's spread, a statewide community lockdown was implemented, confining nursing home patients and prohibiting outside contact and movement. This study found that donor screening for fecal microbiota transplantation is likely to fail due to a high frequency of extended-spectrum beta-lactamase positive bacteria in feces, poor adherence to regular fecal donation, increased social isolation, travel restrictions, and decreased antibiotic use. Conventional lactamase antagonists may decrease ESBLs, which cause cephalosporin resistance in certain bacteria. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains are increasing, and the COVID-19 pandemic triggered a critical care unit pandemic. This study found that gram-negative antibiotic resistance was 1.11-fold higher among those without documented attempts to improve infection prevention, treatment, or prescription safety. More efforts need to be made to prevent infections, offer treatments, and monitor medication resistance. These activities are all vital.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
